PubMed:23511244 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/23511244","sourcedb":"PubMed","sourceid":"23511244","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23511244","text":"Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.\nBACKGROUND: Previous evidence indicates that pioglitazone may improve dyslipidemia in patients with Type 2 diabetes mellitus (T2DM).\nAIM: The primary objective of this study was to evaluate the effect of either pioglitazone or placebo with metformin on levels of serum HDL cholesterol (HDL-C) in patients with T2DM. A secondary objective evaluated changes in metabolic syndrome (MS)-specific parameters.\nSUBJECTS AND METHODS: This multicenter, double-blind, randomized study was performed in patients with T2DM treated with metformin and hemoglobin A1c (HbA1c) levels between 6-8%, central obesity and reduced HDL-C. MS was evaluated from global changes in parameter values and expressed as a single factorial score following multivariate analysis of each parameter. 213 patients (110 in the pioglitazone group and 103 in the placebo group) were available for intention-to-treat analysis.\nRESULTS: Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6.3 mg/dl vs 3.0 mg/dl; p\u003c0.01) in addition to a greater reduction in the extent of MS (-13.2 vs -4.9; p=0.0055). Upon study completion, patients treated with pioglitazone had lower levels of HbA1c (6.41±0.65 vs 6.96±0.74%; p\u003c0.001) and homeostasis model assessment-insulin resistance (HOMA-IR) (2.88±1.95 vs 4.68±3.63; p=0.013) and a reduction of the atherogenic LDL subfraction (pattern B) (-5.7%).\nCONCLUSIONS: The beneficial effects observed in pioglitazone-treated patients in the present study, (i.e. the increase in HDL-C and the reduction of insulin resistance and atherogenic LDL subfractions), support findings from the PROactive trial, where pioglitazone showed pleiotropic effects and reduced death, fatal myocardial infarction (MI) and non-fatal MI in T2DM patients with MS. Furthermore, medication used in this study showed good tolerability.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_23511244_0_0","span":{"begin":0,"end":59},"obj":"expanded"},{"id":"SS2_23511244_0_0","span":{"begin":61,"end":67},"obj":"abbr"},{"id":"SS1_23511244_2_0","span":{"begin":253,"end":277},"obj":"expanded"},{"id":"SS2_23511244_2_0","span":{"begin":279,"end":283},"obj":"abbr"},{"id":"SS1_23511244_4_0","span":{"begin":422,"end":437},"obj":"expanded"},{"id":"SS2_23511244_4_0","span":{"begin":439,"end":444},"obj":"abbr"},{"id":"SS1_23511244_5_0","span":{"begin":512,"end":530},"obj":"expanded"},{"id":"SS2_23511244_5_0","span":{"begin":532,"end":534},"obj":"abbr"},{"id":"SS1_23511244_7_0","span":{"begin":691,"end":705},"obj":"expanded"},{"id":"SS2_23511244_7_0","span":{"begin":707,"end":712},"obj":"abbr"},{"id":"SS1_23511244_12_0","span":{"begin":1384,"end":1431},"obj":"expanded"},{"id":"SS2_23511244_12_0","span":{"begin":1433,"end":1440},"obj":"abbr"},{"id":"SS1_23511244_14_0","span":{"begin":1865,"end":1886},"obj":"expanded"},{"id":"SS2_23511244_14_0","span":{"begin":1888,"end":1890},"obj":"abbr"}],"relations":[{"id":"AE1_23511244_0_0","pred":"abbreviatedTo","subj":"SS1_23511244_0_0","obj":"SS2_23511244_0_0"},{"id":"AE1_23511244_2_0","pred":"abbreviatedTo","subj":"SS1_23511244_2_0","obj":"SS2_23511244_2_0"},{"id":"AE1_23511244_4_0","pred":"abbreviatedTo","subj":"SS1_23511244_4_0","obj":"SS2_23511244_4_0"},{"id":"AE1_23511244_5_0","pred":"abbreviatedTo","subj":"SS1_23511244_5_0","obj":"SS2_23511244_5_0"},{"id":"AE1_23511244_7_0","pred":"abbreviatedTo","subj":"SS1_23511244_7_0","obj":"SS2_23511244_7_0"},{"id":"AE1_23511244_12_0","pred":"abbreviatedTo","subj":"SS1_23511244_12_0","obj":"SS2_23511244_12_0"},{"id":"AE1_23511244_14_0","pred":"abbreviatedTo","subj":"SS1_23511244_14_0","obj":"SS2_23511244_14_0"}],"attributes":[{"subj":"SS1_23511244_0_0","pred":"source","obj":"Allie"},{"subj":"SS2_23511244_0_0","pred":"source","obj":"Allie"},{"subj":"SS1_23511244_2_0","pred":"source","obj":"Allie"},{"subj":"SS2_23511244_2_0","pred":"source","obj":"Allie"},{"subj":"SS1_23511244_4_0","pred":"source","obj":"Allie"},{"subj":"SS2_23511244_4_0","pred":"source","obj":"Allie"},{"subj":"SS1_23511244_5_0","pred":"source","obj":"Allie"},{"subj":"SS2_23511244_5_0","pred":"source","obj":"Allie"},{"subj":"SS1_23511244_7_0","pred":"source","obj":"Allie"},{"subj":"SS2_23511244_7_0","pred":"source","obj":"Allie"},{"subj":"SS1_23511244_12_0","pred":"source","obj":"Allie"},{"subj":"SS2_23511244_12_0","pred":"source","obj":"Allie"},{"subj":"SS1_23511244_14_0","pred":"source","obj":"Allie"},{"subj":"SS2_23511244_14_0","pred":"source","obj":"Allie"}]},{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":260,"end":277},"obj":"HP_0000819"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubmedHPO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#df93ec","default":true},{"id":"PubmedHPO","color":"#93ecc5"}]}]}}